Floatz logo

(±)-FTC

Fatty Liver Disease

Fundacion SEIMC-GESIDASmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Metformin
Leiden University Medical Center
Phase 4BBB
Alpha Tocopherol
Yuen Kah Hay
Phase 4BB
Dolutegravir
Fundacion SEIMC-GESIDA
Phase 4BB
Rilpivirine
Fundacion SEIMC-GESIDA
Phase 4BB
Raltegravir
Helsinki University Central Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

(±)-FTC is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative ·
66 / 100
View asset →
Impaired CognitionDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →